Proton Therapy
17
10
11
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (17)
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
HUmanitas PROtontherapy (HU-PRO)
Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy
Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
Virtual Reality for Children in Radiotherapy (REVER)
Safety and Efficacy of IMPT or IMRT for Breast Cancer
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
Proton Therapy for Locally Advanced Cervical Cancer
HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC
Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas
Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tumors
Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received
Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer
Combination of Hypofractionated Proton Therapy With Immunotherapy
Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial